Ingenious Brit scientists have developed a 'Star Trek'-style medical "tricorder" capable of diagnosing diseases such as breast cancer in minutes.
The hand-held device analyses a patient's blood, urine or saliva sample to indicate the presence of disease, much like the one used by Dr Leonard "Bones" McCoy in the sci-fi series.
Breast Cancer during Pregnancy
Management of breast cancer during pregnancy or pregnancy associated breast cancer requires special consideration to avoid harm to the fetus.
Advertisement
Named the CliniHub, the gadget features a number of "ports" into which samples are placed.
The samples react to chemicals inside the ports, which then change colour to denote diseases in the same way that a pregnancy test turns blue.
![Women and Cancer]( "Women and Cancer")
Cancer is one of the frequently talked about and most feared disease that falls under the genre of lifestyle diseases that have evolved, rather rapidly, in the past two decades.
CliniHub has been developed by Cambridge Consultants in conjunction with US firm XenBio Fluidics, from California.
Patrick Pordage, from Cambridge Consultants, believes it could be "the future" for diagnosing diseases.
"We are very excited about the possibilities that CliniHub can bring to both patients and GPs across the world," the Scotsman quoted him as saying.
"Quicker analysis of diseases can only lead to better treatment and, in some cases, we hope it could save lives. This technology is a real breakthrough for us.
"The CliniHub could prove to be the future of disease diagnosis and we believe its applications will grow with time," he added.
The netbook-sized CliniHub is expected to cost about 650 pounds.
Its developers predict it will soon be able to detect up to 20 ailments and become commonplace in GP surgeries.
When using the device, doctors insert a blood, urine or saliva sample into one of four USB-sized ports located on the side.
Each port contains a chemical "assay" that has been designed in the US to react in different ways when it detects different antibodies and diseases.
Source: ANI
Women and Cancer
Cancer is one of the frequently talked about and most feared disease that falls under the genre of lifestyle diseases that have evolved, rather rapidly, in the past two decades.
Advertisement
CliniHub has been developed by Cambridge Consultants in conjunction with US firm XenBio Fluidics, from California.
Patrick Pordage, from Cambridge Consultants, believes it could be "the future" for diagnosing diseases.
"We are very excited about the possibilities that CliniHub can bring to both patients and GPs across the world," the Scotsman quoted him as saying.
"Quicker analysis of diseases can only lead to better treatment and, in some cases, we hope it could save lives. This technology is a real breakthrough for us.
"The CliniHub could prove to be the future of disease diagnosis and we believe its applications will grow with time," he added.
The netbook-sized CliniHub is expected to cost about 650 pounds.
Its developers predict it will soon be able to detect up to 20 ailments and become commonplace in GP surgeries.
When using the device, doctors insert a blood, urine or saliva sample into one of four USB-sized ports located on the side.
Each port contains a chemical "assay" that has been designed in the US to react in different ways when it detects different antibodies and diseases.
Source: ANI
Breast Lumps
Most breast lumps are caused by hormonal changes in a woman and may not be cancerous. Common causes of breast lumps include fibroadenosis, breast cancer, breast cyst.
Advertisement
 Breast Lumps-ScreeningBreast lumps must never be neglected but instead be subjected to medical examination to rule out cancer. | Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News
The combination of the personalized cancer vaccine with ACT led to ovarian cancer control in few patients within a span of three months, stated study results.
Uncovering key kinases in tumor growth and invasion is crucial for improving targeted therapies in advanced-stage colorectal cancer.
The study findings validate metal-enhanced photo-oxidation for future metal-based anticancer drugs.
Mutations in 11 genes are linked to aggressive forms of prostate cancer, which may present novel therapeutic and therapy options.
Improved oral health, as indicated by the count of natural teeth and dental appointments preceding the diagnosis, correlated with enhanced head and neck cancer survival rates.
